Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Puma's Nerlynx Scores Broad Label Across Adjuvant Breast Cancer Subgroups

Executive Summary

US FDA labeling details the differences in performance of neratinib in adjuvant breast cancer by subgroup, as well as results relative to the timing of Roche's Herceptin, but the drug's indication covers all.

Advertisement

Related Content

SOPHIA Positions MacroGenics' Margetuximab For Role In HER2-Positive Breast Cancer
Puma Beats Most Of Stock Drop Suit Over Nerlynx Study Statements
Deal Watch: Avid Transitions Into CDMO By Offloading Cancer Program To Oncologie
Deal Watch: Sanofi Finds Ideal 'Partner' For Leukine
Puma's Likely Neratinib EU Knockback May Be Temporary
Keeping Track Of Novel Agents: US FDA Approves Nerlynx And Vosevi, Turns Down Evenity; Macrilen Returns
Puma May Face Marketing Hurdles Even If Neratinib Wins Final Approval
Neratinib’s FDA Panel Nod Weighed Down By Indication Breadth Worries
Puma’s Neratinib Brings Uncertain Efficacy, Tolerability Concerns To FDA Panel

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS121126

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel